Outlook Therapeutics Files Definitive Proxy Statement

TL;DR

Outlook Therapeutics filed its proxy statement for the Aug 12 meeting. Vote on directors & pay.

AI Summary

Outlook Therapeutics, Inc. filed its definitive proxy statement on June 26, 2024, for its annual meeting of stockholders scheduled for August 12, 2024. The filing details the company's governance, executive compensation, and proposals to be voted on by shareholders. The company, formerly known as Oncobiologics, Inc., is in the biological products sector.

Why It Matters

This filing provides shareholders with crucial information to make informed voting decisions on company matters, including director elections and executive compensation, impacting the company's future direction.

Risk Assessment

Risk Level: medium — Proxy statements are routine filings, but the specific proposals and company performance can introduce medium-level risk depending on shareholder sentiment and company outlook.

Key Players & Entities

• Outlook Therapeutics, Inc. (company) — Registrant
• Oncobiologics, Inc. (company) — Former Company Name
• August 12, 2024 (date) — Annual Meeting Date
• June 26, 2024 (date) — Filing Date

FAQ

Key Financial Figures

• $1,000,000 — non-employee director, will not exceed $1,000,000 in total value (increased from $400,000
• $400,000 — ,000,000 in total value (increased from $400,000 in the 2015 Plan), or in the event such
• $1,500,000 — d to the Board during such fiscal year, $1,500,000 in total value. For purposes of this li
• $16.63 — se price of outstanding stock options $16.63 Weighted-average remaining term of ou
• $7.56 — s reported on Nasdaq Stock Market LLC $7.56 (1) A "full value award" is any awa

Filing Documents

• tm2417053-2_def14a.htm (DEF 14A) — 799KB
• lg_outlooktherapeutics-4clr.jpg (GRAPHIC) — 18KB
• bc_companytsr-4c.jpg (GRAPHIC) — 52KB
• bc_netincome-4c.jpg (GRAPHIC) — 49KB
• px_24outlookproxy1pg01-bw.jpg (GRAPHIC) — 295KB
• px_24outlookproxy1pg02-bw.jpg (GRAPHIC) — 262KB
• 0001104659-24-074966.txt ( ) — 1679KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 20

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 24 Summary Compensation Table 24 Narrative to Summary Compensation Table 25 Outstanding Equity Awards at Fiscal Year End 27 March 2024 Option Awards 28 Clawback Policy 28 Hedging Transactions 29 DIRECTOR COMPENSATION 30 Non-Employee Director Compensation Policy 30 PAY VERSUS PERFORMANCE 33 Analysis of the Information Presented in the Pay versus Performance Table 35 HOUSEHOLDING OF PROXY MATERIALS 37 OTHER MATTERS 38 APPENDIX A OUTLOOK THERAPEUTICS, INC. 2024 EQUITY INCENTIVE PLAN A-1 i TABLE OF CONTENTS OUTLOOK THERAPEUTICS, INC. 111 S. Wood Avenue, Unit #100, Iselin, New Jersey 08830 (609) 619-3990 PROXY STATEMENT FOR THE SPECIAL MEETING OF STOCKHOLDERS TO BE HELD ON AUGUST 12, 2024 QUESTIONS AND ANSWERS ABOUT THE SPECIAL MEETING Why am I receiving these materials? We have sent you this proxy statement and the Proxy Card, or collectively, the Proxy Materials, because the Board of Directors, or the Board, of Outlook Therapeutics, Inc., sometimes referred to as the Company or Outlook Therapeutics, is soliciting your proxy to vote at the special meeting of stockholders, or the Special Meeting, including any adjournment or postponement thereof. This proxy statement summarizes the information you will need to know to cast an informed vote at the Special Meeting. You are invited to attend the Special Meeting to vote on the proposal described in this proxy statement. However, you do not need to attend the Special Meeting to vote your shares. Instead, you may simply complete, sign and return the enclosed Proxy Card, or follow the instructions below to submit your proxy over the telephone or through the internet. We intend to begin mailing these Proxy Materials on or about July 1, 2024 to all stockholders of record entitled to vote at the Special Meeting. How do I attend the Special Meeting? The Special Meeting will be held on Monday, August 12, 2024, at 9:00 a.m. Centra

View Full Filing

View this DEF 14A filing on SEC EDGAR